Published in Drug Week, February 17th, 2006
Xerecept is currently in phase III trials for peritumoral brain edema.
NTI received $20 million on November 28, 2005 and subsequent payments will be received in June 2006 and January 2007. Should Xerecept meet certain regulatory milestones, up to an additional $15 million would be paid to the company. If Xerecept receives regulatory approval and is ultimately commercialized, the company would also be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.